Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Institute on Aging (NIA)
Study ID
NCT00087425
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • bryostatin 1 — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy, such as bryostatin 1, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Bryostatin 1 may help rituximab kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving bryostatin 1 together with rituximab works in treating patients with B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia that has not responded to previous treatment with rituximab.

Key Dates

Start date
Jul 31, 2004
Status verified
Jan 2007
Primary completion
Oct 31, 2007

Study Design

Enrollment
48 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Feasability and safety

Locations (1)

FacilityCityStateZIPSite coordinators
NIH - Warren Grant Magnuson Clinical CenterBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
NIH - Warren Grant Magnuson Clinical Center· Bethesda, MD

Related Studies